Needham & Company LLC Reaffirms “Buy” Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Needham & Company LLC reiterated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report published on Thursday morning,Benzinga reports. They currently have a $207.00 price target on the specialty pharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the company. JPMorgan Chase & Co. lifted their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research report on Monday, August 19th. Robert W. Baird upped their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. Piper Sandler reaffirmed an “overweight” rating and set a $163.00 price objective (down previously from $166.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. Royal Bank of Canada reiterated an “outperform” rating and issued a $179.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $177.00.

Jazz Pharmaceuticals Stock Up 2.4 %

JAZZ opened at $123.60 on Thursday. The company has a 50 day moving average of $117.11 and a 200 day moving average of $111.99. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a 12 month low of $99.06 and a 12 month high of $134.17. The company has a market cap of $7.47 billion, a PE ratio of 17.41, a price-to-earnings-growth ratio of 1.02 and a beta of 0.57.

Insider Buying and Selling

In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the transaction, the chief executive officer now owns 428,976 shares in the company, valued at approximately $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,753 shares of company stock worth $816,289 in the last 90 days. 4.20% of the stock is owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors have recently modified their holdings of the company. EverSource Wealth Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares during the period. GAMMA Investing LLC raised its holdings in shares of Jazz Pharmaceuticals by 41.3% during the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 121 shares in the last quarter. Arizona State Retirement System lifted its stake in Jazz Pharmaceuticals by 0.8% in the second quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company’s stock worth $1,770,000 after acquiring an additional 130 shares during the period. Coldstream Capital Management Inc. boosted its holdings in Jazz Pharmaceuticals by 7.7% in the third quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock valued at $259,000 after acquiring an additional 165 shares in the last quarter. Finally, Itau Unibanco Holding S.A. increased its position in Jazz Pharmaceuticals by 63.2% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after purchasing an additional 172 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.